Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.63, $0.28 better than the analyst estimate of $0.35. Revenue for the quarter came in at $91.2 million versus the consensus estimate of $91.33 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.